Back

Elevated markers of liver function are associated with poorer outcomes in HFREF: an analysis of DAPA-HF

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Chronic heart failure e-posters Pharmacotherapy ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Ms Lorna Cowan

Glasgow (United Kingdom of Great Britain & Northern Ireland)

218 More presentations in this session

Presentation thumbnail
Intermittent therapy with levosimendan in patients with advanced heart failure
Professor M. Weis (Munich, DE)
Abstract Slides
Presentation thumbnail
Differences in long-term all-cause and cardiovascular mortality according to heart failure aetiology in ambulatory patients
Doctor G. Spitaleri (Sant Joan Despi (Barcelona), ES)
Abstract Slides
Presentation thumbnail
Comparing the central arterial stiffness indices in the decompensated and compensated states of heart failure: a cohort study
Assistant Professor G. Youssef (Cairo, EG)
Abstract Slides
Presentation thumbnail
Opportunities for clinician education in the pharmacotherapy of stable heart failure
Doctor P. Murray (Toronto, CA)
Abstract Slides
Presentation thumbnail
Systolic blood pressure visit-to-visit variability and clinical outcomes of heart failure with preserved ejection fraction
Doctor Q. Zhang (Tianjin, CN)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure e-posters

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
The impact of nonalcoholic fatty liver disease on ultrasound parameters of congestion and prognosis in heart failure patients.
22 May 2023
thumbnail
Congress Presentation
Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF
29 August 2020
thumbnail
Congress Presentation
Aspartate aminotransferase to alanine aminotransferase ratio is associated with frailty and mortality in older patients with heart failure
29 June 2021
thumbnail
Congress Presentation
Myeloperoxidase as a prognostic marker for adverse events in patients with chronic heart failure in 12 month follow-up
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources